Receptor tyrosine kinase alterations in AML - biology and therapy
- PMID: 20306247
- DOI: 10.1007/978-0-387-69259-3_6
Receptor tyrosine kinase alterations in AML - biology and therapy
Abstract
Acute myeloid leukemia (AML) is the most common form of leukemia in adults, and despite some recent progress in understanding the biology of the disease, AML remains the leading cause of leukemia-related deaths in adults and children. AML is a complex and heterogeneous disease, often involving multiple genetic defects that promote leukemic transformation and drug resistance. The cooperativity model suggests that an initial genetic event leads to maturational arrest in a myeloid progenitor cell, and subsequent genetic events induce proliferation and block apoptosis. Together, these genetic abnormalities lead to clonal expansion and frank leukemia. The purpose of this chapter is to review the biology of receptor tyrosine kinases (RTKs) in AML, exploring how RTKs are being used as novel prognostic factors and potential therapeutic targets.
Similar articles
-
Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.Curr Hematol Malig Rep. 2006 Jun;1(2):101-7. doi: 10.1007/s11899-006-0020-9. Curr Hematol Malig Rep. 2006. PMID: 20425339 Review.
-
New Models of Therapy: When Acute Leukemia Becomes Chronic.Biol Blood Marrow Transplant. 2015 Oct;21(10):1856-7. doi: 10.1016/j.bbmt.2015.07.011. Epub 2015 Jul 14. Biol Blood Marrow Transplant. 2015. PMID: 26183079 No abstract available.
-
AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017. Epub 2010 Apr 7. Exp Hematol. 2010. PMID: 20380868
-
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.Crit Rev Oncol Hematol. 2007 Sep;63(3):215-30. doi: 10.1016/j.critrevonc.2007.05.005. Epub 2007 Jul 19. Crit Rev Oncol Hematol. 2007. PMID: 17658267 Review.
-
Relative receptor tyrosine kinases and anti-apoptotic transcripts hold potential for predicting inferior outcome in adult acute myeloid leukemia: a prospective pilot study.Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):501-508.e2. doi: 10.1016/j.clml.2014.04.005. Epub 2014 Jun 11. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25065779
Cited by
-
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.Blood. 2023 Jan 19;141(3):244-259. doi: 10.1182/blood.2022016580. Blood. 2023. PMID: 36206490 Free PMC article.
-
The Research Advances of Aptamers in Hematologic Malignancies.Cancers (Basel). 2023 Jan 1;15(1):300. doi: 10.3390/cancers15010300. Cancers (Basel). 2023. PMID: 36612296 Free PMC article. Review.
-
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.Leuk Res. 2013 Nov;37(11):1461-7. doi: 10.1016/j.leukres.2013.07.034. Epub 2013 Aug 6. Leuk Res. 2013. PMID: 23993427 Free PMC article. Clinical Trial.
-
Heme controls the regulation of protein tyrosine kinases Jak2 and Src.Biochem Biophys Res Commun. 2010 Dec 3;403(1):30-5. doi: 10.1016/j.bbrc.2010.10.101. Epub 2010 Oct 29. Biochem Biophys Res Commun. 2010. PMID: 21036157 Free PMC article.
-
Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials. 2015 Oct;67:42-51. doi: 10.1016/j.biomaterials.2015.07.025. Epub 2015 Jul 15. Biomaterials. 2015. PMID: 26204224 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous